Form D · Pharmaceuticals
Epigenetx, LLC
St. Louis, MO · CIK 0001601515
Offering snapshot reported Mar 6, 2014 · SEC filing
- Reported sold
- $170K Offering amount: $1.17M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $2K Reported outside-investor minimum
- First sale
- Feb 21, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 6, 2014 | Initial | $170,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-213042
Source: Form D, filed Mar 6, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Beardsley | Director, Executive |
| Alan Macinnes | Director, Executive |
| Garland Marshall | Director |
| Rino Ragno | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
4041 Forest Park Parkway
St. Louis, MO, 63108
St. Louis, MO, 63108